Clinical Trials Sponsored by Abbisko Therapeutics Co, Ltd

Total 193 results

Abbisko Therapeutics Co, Ltd

Recruiting

A Mass Balance Study of [14C]ABSK021

Healthy Subjects

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase II Study Evaluating the Efficacy and Safety of ABSK021 (Pimicotinib)) in the Treatment of cGvHD Chronic Graft Versus Host Disease (cGvHD)

cGvHD

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors

Solid Tumor

United States, China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 1b/2 Clinical Study to Evaluate the Safety and Tolerability and Efficacy of AZD4547

Urothelial Carcinoma

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor

Advanced Liver Cancer

China
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Clinical Trial to Evaluate the Effect of Itraconazole and Rifampicin on ABSK021

Healthy Subjects

China
Abbisko Therapeutics Co, Ltd

Completed

ABSK091 Food Effect Study in Healthy Subjects

Health, Subjective | Food-drug Interaction

Taiwan
Abbisko Therapeutics Co, Ltd

Not yet recruiting

A Clinical Trial to Evaluate a High-Fat Meal and Omeprazole Enteric-coated Tablets on ASBK021

Healthy Subjects
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK112 in Patients With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

China, United States
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2 Study of ABSK021 in Patients With Advanced Pancreatic Cancer

Advanced Pancreatic Cancer

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Evaluate the Safety and Efficacy of AZD4547 Combination With Tislelizumab in Patients With mUC

Urothelial Carcinoma

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Phase 2, Open-Label Study of ABSK-011 Combined Atezolizumab in HCC Patients

Hepatocellular Carcinoma

China
Abbisko Therapeutics Co, Ltd

Enrolling by invitation

A Study to Assess the Safety, Tolerability and Antitumor Activity of X4P-001 in Combination With TNBC

Triple Negative Breast Cancer

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules

Healthy Subjects

China
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK121-NX in Patients With Advanced Solid Tumors

Solid Tumor

United States, China
Abbisko Therapeutics Co, Ltd

Not yet recruiting

ABSK021 Food Effect Study in Healthy Subjects

Neoplasms
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK043 in Patients With Advanced Solid Tumor

Neoplasms

Australia
Abbisko Therapeutics Co, Ltd

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Neoplasms | Tenosynovial Giant Cell Tumor

United States
Abbisko Therapeutics Co, Ltd

Active, not recruiting

Study of Pimicotinib (ABSK021) for Tenosynovial Giant Cell Tumor (MANEUVER)

Tenosynovial Giant Cell Tumor | Giant Cell Tumor of Tendon Sheath | Pigmented Villonodular Synovitis

Spain, China, United States, Netherlands, Italy, Canada, Poland
Ranok Therapeutics (Hangzhou) Co., Ltd.

Recruiting

A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)

Advanced Solid Tumor | DLBCL

United States
OriCell Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

Cardiovascular Diseases | Vascular Diseases | Neoplasms | Immune System Diseases | Neoplasms by Histologic Type | Lymphoproliferative Disorders | Immunoproliferative Disorders | Hematologic Diseases | Hemostatic Disorders | Hemorrhagic Disorders | Multiple Myeloma | Neoplasms, Plasma Cell | Paraproteinemias | Blood...

United States
iRegene Therapeutics Co., Ltd.

Recruiting

The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease

Parkinson Disease

China
BIXINK Therapeutics Co., Ltd.

Recruiting

An ERP-based Mobile Intervention as an Adjunctive Treatment for OCD

Obsessive-Compulsive Disorder | Obsessive-compulsive Disorders and Symptoms

United States
Lumosa Therapeutics Co., Ltd.

Recruiting

A Study to Evaluate Safety and PK of Multiple Doses of LT3001 Drug Product and Drug-drug Interaction in Healthy Subjects

Acute Ischemic Stroke

United States
Lumosa Therapeutics Co., Ltd.

Unknown

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Acute Ischemic Stroke

Taiwan, United States
Lumosa Therapeutics Co., Ltd.

Completed

A Study of Intramuscular Sebacoyl Dinalbuphine Ester for Post-Hemorrhoidectomy Pain Management

Pain | Analgesia Disorder

Taiwan
CytosinLab Therapeutics Co., Ltd.

Recruiting

CTS2190 Phase I /II Clinical Study in Patients

Pancreatic Cancer | Non-small Cell Lung Cancer | Solid Tumors | Triple-negative Breast Cancer

China
iN Therapeutics Co., Ltd.

Recruiting

A MAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers and PHN Patients.

Pain | Osteoarthritis | Chronic Pain | Neuropathic Pain | Post Herpetic Neuralgia

Australia
OriCell Therapeutics Co., Ltd.

Recruiting

Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC

Hepatocellular Carcinoma

China
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects (BRIGHT)

Acute Ischemic Stroke
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Acute Ischemic Stroke
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Clinical Trial to Evaluate Zevor-cel (CT053) in Patients With Relapsed and/or Refractory Multiple Myeloma (LUMMICAR STUDY 2)

Multiple Myeloma

United States, Canada
iN Therapeutics Co., Ltd.

Completed

A SAD Study to Evaluate the Safety, Tolerability and PK/PD of iN1011-N17 in Healthy Volunteers

Pain | Osteoarthritis

Australia
Lumosa Therapeutics Co., Ltd.

Completed

A Bioavailability Study of NALDEBAIN ER Injection and Nalbuphine Injection in Healthy Volunteers.

Health

United States
Lumosa Therapeutics Co., Ltd.

Unknown

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

Uremic Pruritus

Taiwan
CARsgen Therapeutics Co., Ltd.

Unknown

Anti-GPC3 CAR T for Recurrent or Refractory Lung Squamous Cell Carcinoma

Lung Squamous Cell Carcinoma

China
Lumosa Therapeutics Co., Ltd.

Completed

A Bioavailability Study of Sebacoyl Dinalbuphine Ester IM Injection in Healthy Volunteers

Pain | Analgesia Disorder

Taiwan
CARsgen Therapeutics Co., Ltd.

Not yet recruiting

Anti-GPRC5D CAR-T Cells (CT071) in Participants With RRMM or RRpPCL

Multiple Myeloma | Primary Plasma Cell Leukemia
CorrectSequence Therapeutics Co., Ltd

Not yet recruiting

A Safety and Efficacy Study Evaluating CS-101 in Subjects With β-Thalassemia Major

Beta-Thalassemia Major

China
Sirius Therapeutics Co., Ltd.

Recruiting

A Phase 1 Study to Evaluate the Safety, Tolerability, PK/PD of SRSD107 in Healthy Participants

Thrombosis

Australia
OriCell Therapeutics Co., Ltd.

Enrolling by invitation

OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM

Relapsed and/or Refractory Multiple Myeloma

China
CARsgen Therapeutics Co., Ltd.

Active, not recruiting

Claudin18.2 CAR-T (CT041) in Patients With Gastric, Pancreatic Cancer, or Other Specified Digestive Cancers

Gastric Cancer | Pancreatic Cancer

United States, Canada
Windtree Therapeutics
CVie Therapeutics Co. Ltd.

Completed

The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure

Acute Decompensated Heart Failure

China, Italy
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

An Open Label Extension Study to Evaluate the Safety of Continued Therapy of Subcutanous Remodulin® in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
United Therapeutics
CVie Therapeutics Co. Ltd.

Withdrawn

Safety, Tolerability, Pharmacokinetics and Efficacy of Two Different Rates of Subcutanous Remodulin® Dose Titration in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

China
HuidaGene Therapeutics Co., Ltd.
Cholgene Therapeutics, Inc.

Recruiting

Safety and Efficacy Trial of HG004 for Leber Congenital Amaurosis Related to Rpe65 Gene Mutations (STAR) (STAR)

Leber Congenital Amaurosis | Inherited Retinal Diseases Caused by RPE65 Mutations

United States, China
MediLink Therapeutics (Suzhou) Co., Ltd.

Recruiting

A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC

Metastatic Castration-resistant Prostate Cancer (mCRPC)

China
Cutia Therapeutics（Wuxi）Co.,Ltd

Recruiting

A Phase 2 Clinical Study of CU-20401

Efficacy and Safety

China
Axter Therapeutics (Beijing) Co., Ltd

Recruiting

Study of AXT-1003 in Adult Subjects With Relapsed/Refractory Non-Hodgkin Lymphomas

Relapsed or Refractory Non-Hodgkin's Lymphoma

China
Suzhou BlueHorse Therapeutics Co., Ltd.

Recruiting

A Clinical Study on LM103 for the Treatment of Advanced Solid Tumors

Solid Tumor

China

Clinical Trials Sponsored by Abbisko Therapeutics Co, Ltd

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations